Abstract
Background
Oral anticoagulant use continues to increase rapidly. In this setting, it is important to recognise that some normal individuals can demonstrate resistance to anticoagulation with warfarin. Such patients require high daily doses of warfarin (>20 mg) in order to maintain an international normalised ratio (INR) within the target therapeutic range (2–3). We describe the case of an elderly gentleman with atrial fibrillation who demonstrated true warfarin resistance.
Methods
We performed vitamin K epoxide reductase subunit 1 (VKORC1) gene coding sequence analysis using polymerase chain reaction primers.
Results
We demonstrated that our patient was heterozygous for a 383 T→G transition in exon 2 of the VKORC1 gene.
Conclusions
This is the first documented Irish case of true warfarin resistance as a result of a mutation in VKORC1, a novel gene encoding a component of the epoxide reductase enzyme complex which is an essential component in the recycling pathway of vitamin K and is postulated to be one of the sites of action of warfarin.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Suttie JW (1987) The biochemical basis of warfarin therapy. Adv Exp Med Biol 214:3–16
Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427(6974):541–4
Rost S, Fregin A, Ivaskevicius V et al (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537–41
Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356(9242):1667–71
Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD (2005) Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 93(1):23–6
O’Reilly RA, Aggeler PM, Hoag MS, Leong LS, Kropatkin ML (1964) Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N Engl J Med 271:809–15
Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM (2005) A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 3(7):1533–5
Acknowledgments
We wish to thank the staff of the coagulation laboratory of St Vincent’s University Hospital, Elm Park, Dublin.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Áinle, F.N., Mumford, A., Tallon, E. et al. A vitamin K epoxide reductase complex subunit 1 mutation in an Irish patient with warfarin resistance. Ir J Med Sci 177, 159–161 (2008). https://doi.org/10.1007/s11845-008-0126-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-008-0126-2